Transient Receptor Potential vanilloid 4 ion channel in C-fibres is involved in mechanonociception of the normal and inflamed joint

Frank Richter, Gisela Segond von Banchet & Hans-Georg Schaible

The Transient Receptor Potential vanilloid 4 ion channel (TRPV4) is an important sensor for osmotic and mechanical stimuli in the musculoskeletal system, and it is also involved in processes of nociception. In this study we investigated the putative role of TRPV4 ion channels in joint pain. In anesthetized rats we recorded from mechanosensitive nociceptive Aδ- and C-fibres supplying the medial aspect of the knee joint. The intraarticular injection of the TRPV4 antagonist RN-1734 into the knee joint reduced the responses of C-fibres of the normal joint to noxious mechanical stimulation and the responses of the sensitized C-fibres of the acutely inflamed joint to innocuous and noxious mechanical stimulation. The responses of nociceptive Aδ-fibres were not significantly altered by RN-1734. The intraarticular application of the TRPV4 agonists 4αPDD, GSK 1016790 A, and RN-1747 did not consistently alter the responses of Aδ- and C-fibres to mechanical stimulation of the joint nor did they induce ongoing activity. We conclude that TRPV4 ion channels are involved in the responses of C-fibres to noxious mechanical stimulation of the normal joint, and in the enhanced sensitivity of C-fibres to mechanical stimulation of the joint during inflammation of the joint.

Mechanical stimuli play a major role in joint pain. In a normal joint pain is elicited by movements which exceed the working range of the joint. When the joint is inflamed, pain is even elicited by movements in the working range of the joint. An important basis of this pattern of joint pain are the response properties of joint nociceptors. Noxious mechanical stimuli applied to the joint (movements exceeding the working range and intense pressure applied to the joint) are encoded by Aδ- and C-fibres which are selectively activated by noxious mechanical stimuli, and by Aβ- and C-fibres which are only weakly activated by innocuous stimuli (movements within the working range, light to moderate local pressure) but respond strongly to noxious mechanical stimuli. During inflammation, nociceptive Aδ- and C-fibres are sensitized. In the sensitized state, the nociceptive fibres show reduced thresholds for activation and increased responses to innocuous and noxious stimuli, thus explaining why mechanical stimuli applied to the inflamed joint are painful.

It is unclear which ion channels in nociceptive neurons are involved in the transduction of mechanical stimuli applied to the joint. A candidate is the Transient Receptor Potential (TRP) vanilloid 4 ion channel (TRPV4). This ion channel, discovered in 2000, is a polymodally activated Ca²⁺-permeable non-selective cation channel that is involved in the transduction of osmotic and mechanical stimuli. Importantly, TRPV4 is also involved in nociception. The channel is expressed in sensory ganglia and free nerve endings in the skin. In behavioural experiments TRPV4 mediated nocifensive behaviours to increases or decreases of osmolarity and plays a crucial role in mechanical hyperalgesia following inflammatory mediators. TRPV4 knockout mice showed less inflammatory and thermal hyperalgesia induced by capsaicin or carrageenan, impaired sensitivity to acid, an increase in mechanical nociceptive threshold, altered thermal selection behaviours but normal responses to heat and low-threshold mechanical stimuli. TRPV4 may promote the release of SP and CGRP from sensory neurons. A recent study showed that antagonists at the TRPV4 ion channel partially reversed the reduction of grip strength in a model of osteoarthritis suggesting that TRPV4 may also play a role in joint pain.

In the present study we explored the role of TRPV4 in the nociception of the joint in vivo. We recorded from nociceptive sensory fibres of the knee joint in anesthetized rats. This is a well-established approach to investigate
the role of mediators in mechanonociception\textsuperscript{16–18} because it allows to repeatedly stimulate joint nociceptors by noxious mechanical stimuli and to explore how the local application of mediators to the joint alters the responsiveness of the nociceptive nerve fibres to mechanical stimuli. Therefore, single fibre recordings bridge the gap between cellular/molecular mechanisms and behavioural studies which can only measure pain thresholds\textsuperscript{16–18}. For study we selected single nociceptive A\textsubscript{\textdelta}- and C-fibres with a receptive field in the medial aspect of the exposed knee joint. We asked whether the responses to innocuous and noxious rotations are altered by the application of TRPV4 agonists and a TRPV4 antagonist\textsuperscript{19} into the knee joint cavity. Recordings were performed in rats with healthy knee joints and in rats in which the knee joint was acutely inflamed.

Results
We recorded from single A\textsubscript{\textdelta}- and C-fibres of 73 anesthetized rats (usually one fibre per rat). Each sensory fibre had a receptive field in the medial aspect of the knee joint and responded weakly to innocuous but strongly to noxious rotation of the joint. None of the recorded fibres showed ongoing activity. The first sections will describe the effects of the TRPV4 antagonist on the responses to mechanical stimulation.

Effect of the TRPV4 receptor antagonist RN-1734 on the responses of joint afferents to mechanical stimuli applied to the normal knee joint. Figure 1a shows the average changes of the responses of 12 A\textsubscript{\textdelta}-fibres from 12 knee joints to movement stimuli of the normal knee joint at different time points. In 6 knee joints (6 fibres) only the solvent was injected into the knee joint, in another 6 knee joints (6 fibres) the antagonist RN-1734 was injected. The initial baseline responses (control) before the intraarticular injection of the solvent or the antagonist were set to zero, and the different lines show the changes of the responses compared to the baseline value. Neither the solvent nor RN-1734 (500\textmu M) significantly altered the responses to innocuous and noxious rotation of the joint (Fig. 1a). Figure 1b displays the number of action potentials elicited by innocuous and noxious rotation at baseline and at 3 hours after the application of the antagonist. On average, the A\textsubscript{\textdelta}-fibres showed a weak response to innocuous rotation and a much stronger response to noxious rotation, and these responses were not altered by RN-1734. We also determined the torque, necessary for the elicitation of a response to rotation. After application of RN-1734 the mechanical torque thresholds increased non-significantly from 22.0 ± 1.6 to 37.4 ± 8.9 mNm (Fig. 1c). The peristimulus time histograms in the specimen in Fig. 1d display the responses of a typical A\textsubscript{\textdelta}-fibre before and at 3 hours after application of RN-1734.

With the same protocol we tested the effect of RN-1734 (500\textmu M) on the responses of 6 C-fibres from 6 joints, and the solvent was tested in another 7 C-fibres from 7 normal knee joints (Fig. 2). The responses to innocuous and noxious rotations were not significantly altered after application of the solvent into the joint cavity. After the intraarticular application of RN-1734 the responses to innocuous rotation were not altered either but the responses to noxious rotation showed a consistent reduction (Fig. 2a, from the asterisk onwards the responses were significantly reduced compared to the baseline responses; p = 0.0313, Wilcoxon signed rank test). Figure 2b displays the average number of evoked action potentials per stimulus before and at 3 hours after the application of RN-1734, with a significant difference for noxious rotation only (p < 0.0313, Wilcoxon signed rank test). The torque, necessary for the elicitation of a response to rotation, significantly increased after RN-1734 from 13.8 ± 2.2 to 42.4 ± 5.5 mNm (Fig. 2c, p = 0.0047, paired t-test). The specimen of a single fibre in Fig. 2d shows a strong reduction of the responses at 3 hours after RN-1734.

In a further group of four rats we applied the antagonist RN-1734 at a dose of 20\textmu M. After RN-1734 at 20\textmu M the responses of the C-fibres showed a gradual decrease of the numbers of action potentials similar as the responses of the C-fibres after application of the high dose of RN-1734 in the other rats (Fig. 2e). The low dose of 20\textmu M did not influence the number of action potentials in A\textsubscript{\textdelta}-fibres (data not shown). Thus, in the normal joint, the TRPV4 antagonist RN-1734 significantly reduced the responses of C-fibres to noxious rotation but did not influence the responses of A\textsubscript{\textdelta}-fibres.

Effect of the TRPV4 receptor antagonist RN-1734 on the responses of joint afferents to mechanical stimuli applied to the acutely inflamed knee joint. In further experiments we tested whether the antagonist influenced the responses of A\textsubscript{\textdelta}-and C-fibres of the acutely inflamed joint to innocuous and noxious rotation. Inflammation was induced 7–11 hours before the recordings and was therefore fully developed.

The 7 A\textsubscript{\textdelta}-fibres of 7 inflamed knee joints had on average stronger responses to innocuous and noxious rotation than the A\textsubscript{\textdelta}-fibres of the normal joint (innocuous rotation normal joint 23 ± 8 APs/15 s, inflamed joint 90 ± 70 APs/15 s, noxious rotation normal joint 122 ± 35 APs/15 s, inflamed joint 367 ± 58 APs/15 s). However, on average the responses to mechanical stimuli were not significantly reduced by RN-1734 (Fig. 3a, b), and the threshold torque was not significantly influenced either (Fig. 3c).

In the 7 C-fibres of 7 inflamed knee joints in particular the baseline responses to innocuous rotation were enhanced compared to those in the C-fibres of normal joints (128 ± 75 APs/15 s versus 43 ± 21 APs/15 s) whereas the responses to noxious rotation had a similar magnitude as in the normal joint (compare Figs 2b and 4b). In the C-fibres of the inflamed knee joint both the responses to innocuous and noxious rotation were reduced by RN-1734 (p = 0.0469, Wilcoxon signed rank test, Fig. 4a, b), and the threshold torque for an elicitation of a response was enhanced by RN-1734 (p = 0.0082, paired t-test, Fig. 4c). Thus, in the inflamed knee joint the TRPV4 antagonist RN-1734 significantly reduced the responsiveness of the C-fibres to innocuous and noxious rotation but not the responsiveness of the A\textsubscript{\textdelta}-fibres.

Since the different effects of RN-1734 on the average responses of A\textsubscript{\textdelta}-fibres and C-fibres suggested that mainly the C-fibres are influenced by RN-1734, we plotted in Fig. 5 all the fibres recorded from, showing their conduction velocity and the effect of RN-1734. It is evident that with few exceptions only C-fibres were influenced by the TRPV4 antagonist. In the normal joint (fibres with black dots and circles) a decrease of the responses after
RN-1734 was mainly observed in fibres with conduction velocities < 2 m/s, i.e. C-fibres. In the inflamed joint, C-fibres and two fibres with a conduction velocity of about 6 m/s showed a reduction of the responses.

Effects of TRPV4 receptor agonists on the responses of joint afferents to mechanical stimuli applied to the normal knee joint. We explored whether TRPV4 agonists influenced the responses of A\(\delta\)- and C-fibres of the normal joint to innocuous and noxious stimulation. We chose the agonists 4\(\alpha\)PDD, GSK1016790 A, and RN-1747 which were used in different studies as specific TRPV4 agonists.

We monitored action potentials throughout the experiments and therefore we were able to see the generation of action potentials evoked by the application of the compounds themselves. In the first few minutes after intraarticular injections of either buffer or a compound some irregular action potentials could occur in some
experiments but no consistent pattern was observed. However, none of the agonists did evoke ongoing discharges between the stimuli throughout the recording protocol, in the absence of mechanical stimulation. Within the next 2–3 hours we then explored whether the responses of the fibres to mechanical stimulation are altered.

The effects of the agonists on the responses of the A\(\delta\)-fibres is shown in Fig. 6a,b. None of the three agonists significantly influenced the responses of the A\(\delta\)-fibres to innocuous rotation (Fig. 6a). The responses to noxious rotation were not altered by 4\(\alpha\)PDD and RN-1747, but after GSK 1016790 A the responses to noxious rotation were reduced (Fig. 6b). Since GSK 1016790 A did not mimic the effects of 4\(\alpha\)PDD and RN-1747, we did not test more than 3 fibres with GSK 1016790 A. In none of the groups the torque threshold was significantly altered.

Figure 6c,d show the average changes of the responses of C-fibres to innocuous and noxious rotation of the normal joint after intraarticular injection of the agonists. None of the three agonists significantly influenced the responses to innocuous rotation (Fig. 6c). The agonists 4\(\alpha\)PDD and GSK 1016790 A had no effect on the responses to noxious rotation but the agonist RN-1747 reduced the responses to noxious rotation (Fig. 6d). Since RN-1747 had a different effect compared to 4\(\alpha\)PDD and GSK 1016790 A, and since RN-1747 has also effects on TRPM820, we did not test more than 3 neurons (and therefore no statistical evaluation was performed). In none of the groups the torque threshold was significantly altered.

Effects of the TRPV4 receptor agonist 4\(\alpha\)PDD on cultured DRG neurons. In addition to the recordings in vivo, we performed some experiments on cultured DRG neurons. First we explored on fixed DRG neurons the expression of TRPV4 using immunohistochemistry. Second, we explored the effect of 4\(\alpha\)PDD on the intracellular \([Ca^{2+}]\) using calcium imaging. Figure 7a shows the labelling of TRPV4 in a proportion of DRG neurons with an anti-TRPV4 antibody whereas no labelled DRG neurons were seen after adding the control antigen to the primary antibody (Fig. 7b). The areas of the cell bodies of TRPV4-positive DRG neurons are shown in Fig. 7c. The majority of the TRPV4-positive DRG neurons had areas in the range of 100–300 \(\mu\)m\(^2\) thus belonging to DRG neurons with C-fibres (n = 4 independent cultures).
In 5 independent cultures we found that 21 of 144 analysed DRG neurons showed a clear increase of \([\text{Ca}^{2+}]\)

Figure 6a shows an experiment in which 4αPDD induced a transient rise of \([\text{Ca}^{2+}]\) in 3 of 12 individual DRG neurons. All neurons displayed also the typical potassium- (K+) induced rise of \([\text{Ca}^{2+}]\) (showing that cells were responsive) whereas the addition of buffer had no effect.

Discussion
This study investigated the putative role of TRPV4 ion channels in joint pain and provided the following salient results. The intraarticular injection of a TRPV4 antagonist into the knee joint reduced the responses of C-fibres to noxious mechanical stimulation of the normal joint and the responses of sensitized C-fibres to innocuous and noxious mechanical stimulation of the acutely inflamed joint. The responses of Aβ-fibres were not significantly altered by the antagonist, neither in the normal nor in the inflamed joint. The intraarticular application of TRPV4 agonists did not consistently alter the responses of Aβ- and C-fibres to mechanical stimulation. Although the TRPV4 agonist 4αPDD induced a calcium influx in a proportion of isolated cultured DRG neurons, none of the agonists induced ongoing activity of the fibres in vivo. We conclude that TRPV4 ion channels are involved in the C-fibre-mediated mechanonociception of the normal joint and in the mechanical hypersensitivity of the inflamed joint.

In the normal joint the intraarticular application of the TRPV4 antagonist consistently reduced the responses of C-fibres to noxious (painful) rotation of the joint whereas the small responses of the C-fibres to innocuous rotation were not significantly reduced. The most likely interpretation is that noxious rotation opens TRPV4 channels and that the TRPV4 antagonist blocked the Ca^{2+} influx. During inflammation in the joint, C-fibres are sensitized and show stronger responses to innocuous rotation. In the sensitized state also the increased responses to innocuous rotation were blocked suggesting that TRPV4 are involved in both the high threshold mechanonociception in the normal joint as well as in the sensitized mechanonociception in the inflammatory hyperalgesic state.

Figure 3. Influence of the TRPV4 antagonist RN-1734 (500µM) on the responses of Aβ-fibres of the acutely inflamed joint to innocuous and noxious rotation. (a) Time course of the change of the responses to innocuous and noxious rotation after intraarticular injection of RN-1734. In all tested fibres the baseline value before the intraarticular injection (control) was set zero. Baseline values: innocuous rotation RN-1734 group 90 ± 27 APs/15 s, noxious rotation RN-1734 group 367 ± 58 APs/15 s. (b) Responses of Aβ-fibres to innocuous and noxious rotation of the inflamed joint before and at 3 hours after intraarticular application of RN-1734. (c) Torque threshold for the elicitation of action potentials before and at 3 hours after RN-1734. No significant differences.
Interestingly, the TRPV4 antagonist did not alter the responses of A\(\delta\)-fibres of the normal joint. Since we measured the conduction velocity of all recorded neurons we conclude that TRPV4 are predominantly expressed in C-fibres of the joint. However, since in the inflamed joint 2 of 7 fibres with conduction velocities of about 6 m/s showed a reduction of the responses after the antagonist, there might be some plasticity in the expression of TRPV4 in A\(\delta\)-fibres (and in C-fibres). In synoviocytes of the rat temporomandibular joint and in the trigeminal ganglia TRPV4 was upregulated after intraarticular carrageenan injection\(^21\). We found that interleukin-17 which sensitizes C-fibres of the joint to mechanical stimuli and which affects mechanical but not thermal hyperalgesia\(^22\)–\(^24\) up-regulated the expression of TRPV4 but not the expression of TRPV1 ion channels in cultured DRG neurons\(^22\).

Notably, however, in the present study the average responses of A\(\delta\)-fibres to noxious movements did not decrease after RN-1734. The labelling of isolated DRG neurons showed that mainly small-sized neurons showed an expression of TRPV4. Since only few DRG neurons with an area >300 \(\mu\)m\(^2\) were labelled and since medium-sized neurons may be somata of either C- or A\(\delta\)-fibres\(^25\), we did not make an effort to label DRG neurons supplying the joint. In the literature there are very few reports on the conduction velocities of sensory neurons expressing TRPV4. In electrophysiological recordings from primary bladder afferents only a proportion of C-fibres but not A\(\delta\)-fibres were influenced by the TRPV4 agonist GSK1016790A and the TRPV4 antagonist RN-1734\(^26\). The lack of responsiveness of A\(\delta\)-fibres to the antagonist clearly indicates that other mechanosensitive channels must also be involved in mechanonociception. Since both A\(\delta\)- and C-fibres transmit noxious information to the spinal cord\(^3\), the application of an antagonist at TRPV4 channels will probably not have the ability to completely abolish joint pain evoked by mechanical stimuli.

**Figure 4.** Influence of the TRPV4 antagonist RN-1734 (500 \(\mu\)M) on the responses of C-fibres of the acutely inflamed joint to innocuous and noxious rotation. (a) Time course of the change of the responses to innocuous and noxious rotation after intraarticular injection of RN-1734. In all tested fibres the baseline value before the intraarticular injection (control) was set zero. Baseline values: innocuous rotation RN-1734 group 128 ± 77 APs/15 s, noxious rotation RN-1734 group 219 ± 25 APs/15 s. (b) Responses of C-fibres to innocuous and noxious rotation of the inflamed joint before and at 3 hours after intraarticular application of RN-1734. (c) Torque threshold for the elicitation of action potentials before and at 3 hours after RN-1734. *In (a,b) p < 0.0469, Wilcoxon signed-rank test, *in (c) p < 0.0082, paired t-test.
Most of the data with the antagonist RN-1734 were obtained by using a dose of 500 µM. We chose this dose from the work of Wei et al. which was to our knowledge the only in-vivo application of this compound in studies on painful behaviour. Wei et al. injected RN-1734 into the skin of the face or into the paw of rats or applied it topically onto the dura mater at 500 µM. With this dose they found that the induction of allodynia by 4αPDD and RN-1747 could be prevented. Since we applied the compounds into the joint space we chose the same dose, because the joint is well perfused and allows a rapid exchange of substances from the joint. The lack of an effect of the antagonist at 500 µM on Aβ-fibres indicates that TRPV4 ion channels are not involved in their responses to mechanical stimuli. However, since we found a reduction of the responses of C-fibres at 500 µM we explored whether a much lower dose, more close to the IC50 at 3.2 µM would also reduce the responses. As shown in Fig. 2e, the low dose of 20 µM RN-1734 reduced the responses of C-fibres of the normal joint to noxious rotation by the same magnitude as the high dose.

Because TRPV4 can also be activated chemically by specific agonists we explored whether the intraarticular application of TRPV4 agonists induces any noticeable activity or an effect on the responses to mechanical stimulation in vivo. The injection of the compounds did not elicit ongoing discharges nor did we consistently find an influence of these agonists on the magnitude of the responses to innocuous and noxious stimulation (exceptions see below). Since we used the responses to mechanical stimulation as readout parameter we were presumably not able to see an effect of the TRPV4 agonists because mechanical stimulation had opened the TRPV4 channel per se. On the other hand, these data raise doubts whether the chemical opening of the channel per se (as seen in the calcium imaging experiments) is sufficient to elicit action potentials. So far it is not precisely known how mechanical stimuli open TRPV4 ion channels. A complication of using agonists may be their complex effects. For example GSK1016790A regulates the membrane expression of TRPV4. In HEK293 cells GSK1016790A caused a calcium-dependent translocation and internalization of TRPV4 channels within 20 min. Whether other agonists have similar effects is unknown. As mentioned above, RN-1747 may inhibit TRPM8 at an IC50 of 4 µM.

Since DRG neurons express the TRPV4 channel, and since specific TRPV4 agonists can evoke an increase of the intracellular Ca2+ concentration in isolated cultured DRG neurons (see also Segond von Banchet et al.), it is likely that the TRPV4 antagonist blocked TRPV4 channels in the nerve endings in the joint. TRP channels including TRPV4 are transported from the cell body to the endings of the neurons. However, TRPV4 channels are also expressed in other cells of the joint such as chondrocytes and synovial cells. In chondrocytes, mechno/osmosensitive TRPV4 are involved in the sensing of osmolarity, and TRPV4 promotes cartilage extracellular matrix biosynthesis, upregulation of proanabolic and anticatabolic genes and increases in matrix accumulation, and seems to be important for the maintenance of homeostasis in the cartilage. We cannot exclude, therefore, that the antagonist might have also influenced other cells than neurons in the joint. This would not change our conclusion that TRPV4 ion channels are involved in the C-fibre mediated mechanonociception because for the processing of information in the central nociceptive system the sensory outflow from the joint is important.

Antinociceptive effects of the TRPV4 antagonist which are involving other cells than neurons would imply that such cells release, upon activation of TRPV4 channels, mediators which then influence the neurons. This could be well the case because the effects of the antagonist were not immediately fully expressed after injection of the antagonist. This possibility should be further addressed if TRPV4 channels are considered as targets for treatment. In fact, TRPV4 channels in chondrocytes were discussed as targets for treatment, e.g. to prevent the development or progression of OA because insufficient or false functioning of TRPV4 in chondrocytes is thought to be involved in the pathogenesis of OA.

Figure 5. Influence of the TRPV4 antagonist RN-1734 on the responses of nerve fibres of the normal joint (black symbols) and the inflamed joint (red symbols) to noxious rotation. On the x-axis the conduction velocities of the fibres are shown in m/s, on the y-axis the normalised mean changes of the responses to noxious rotation in numbers of action potentials (APs) in the last recording block at three hours after intraarticular application of the antagonist (mean baseline AP numbers are subtracted from the actual numbers of APs).
to promote arthropathies. However, to which extent TRPV4 protects against progression of osteoarthritis remains unclear.

In summary, the present study provides evidence that TRPV4 ion channels significantly contribute to the responses of C-fibres to noxious mechanical stimulation of the normal joint, and to the responses of C-fibres to innocuous and noxious mechanical stimulation of the acutely inflamed joint. The responses of the majority of nociceptive Aβ-fibres was not altered indicating that other mechanosensitive ion channels must be involved in mechanonociception. The failure of the agonists to induce consistent changes of the responses to mechanical stimulation indicates that chemical stimulation of the TRPV4 channels is not sufficient to sensitize TRPV4 channels. More likely the sensitization of TRPV4 to mechanical stimuli is due to inflammatory mediators (see above).

Figure 6. Influence of the TRPV4 agonists 4αPDD (10 µM), GSK 1016790A (10 nM), or RN-1747 (10 µM) on the responses of Aβ- and C-fibres to innocuous and noxious rotation of the normal knee joint. In all graphs the changes of the responses after injection of the agonists are shown, the baseline responses before the injections (control) were set zero. (a) Time course of the change of the responses of Aβ-fibres to innocuous rotation after intraarticular injection of 4αPDD, GSK 1016790A, or RN-1747. Baseline values: 4αPDD group 65 ± 26 APs/15 s, GSK 1016790A group 78 ± 32 APs/15 s, RN-1747 group 44 ± 15 APs/15 s. (b) Time course of the change of the responses of Aβ-fibres to noxious rotation after intraarticular injection of 4αPDD, GSK 1016790A, or RN-1747. Baseline values: 4αPDD group 303 ± 68 APs/15 s, GSK 1016790A group 287 ± 40 APs/15 s, RN-1747 group 194 ± 48 APs/15 s. (c) Time course of the change of the responses of C-fibres to innocuous rotation after intraarticular injection of 4αPDD, GSK 1016790A, or RN-1747. Baseline values: 4αPDD group 109 ± 56 APs/15 s, GSK 1016790A group 9 ± 2 APs/15 s, RN-1747 group 29 ± 23 APs/15 s. (d) Time course of the change of the responses of C-fibres to noxious rotation after intraarticular injection of 4αPDD, GSK 1016790A, or RN-1747. Baseline values: 4αPDD group 139 ± 61 APs/15 s, GSK 1016790A group 98 ± 37 APs/15 s, RN-1747 group 203 ± 103 APs/15 s.
Material and Methods

Electrophysiological recordings from joint afferents. This study was approved by the Thuringian Government (Thüringer Landesamt für Verbraucherschutz) and performed according to the Protection of Animals Act of the Federal Republic of Germany. The rats were treated in accordance with the declaration of Helsinki and the guiding principles in the care and use of animals. Data sampling, evaluation, and presentation complied with the ARRIVE guidelines.

Adult male Wistar rats (n = 73, age > 90 days, body weight 300–400 grams, supplied by the Animal Facility of the University Hospital Jena) were anesthetized with 100 mg/kg sodium thiopentone (Altana, Konstanz, Germany) i.p. and supplemental doses (20 mg/kg i.p.) were applied as necessary to maintain areflexia. Rats breathed spontaneously, mean arterial blood pressure, the electrocardiogram, and body temperature were controlled. The right thigh was exposed from knee joint to groin, a fastener fixed the right femur and the right hind paw was fixed in a shoe-like holder that allowed calibrated rotation of the lower leg in the knee joint. For testing responsiveness of fibres to mechanical stimulation we used innocuous outward torque (20 mNm, 15 s each) and
noxious outward torque (40 mNm, 15 s each). The torque was applied by hand and was adjusted using the readout of a torque gauge (MVD2510, HBK Hottinger-Baldwin, Darmstadt, Germany).

Using platinum wire electrodes, action potentials were recorded from single fibres of the medial articular nerve (MAN) which had receptive fields in the knee joint. The local mechanical threshold in the receptive field was determined with calibrated von Frey hairs (1.6–52 g). The conduction velocity of the nerve fibres (C: \( \leq 1.25 \text{ m/s}, A\theta: 1.25–10 \text{ m/s}, A\geq: \geq 10 \text{ m/s} \)) was determined by electrical stimulation of the mechanical receptive field. Stimulation was performed with a bipolar electrode (pulses of 1–10 V and 0.5 ms duration) and the distance between electrode and recording site was measured. The recorded action potential signals were fed into a PC after recordings the rats were killed with 1.0 mL sodium thiopentone intravenously.

Drugs were washed several times with N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] (HEPES) buffer containing 137 mM NaCl, 5 mM KCl, 1.25 mM NaH₂PO₄ and 25 mM NaHCO₃ (pH 7.3), and air. The cells were fed after an overnight setting with standard medium (2 mL) and used in the next 24 hours.

Primary culture of dorsal root ganglion neurons. Adult Wistar rats were sacrificed with a lethal dose of CO₂. DRGs from all segments of the spinal cord were dissected. Ganglia were incubated at 37 °C with 215 U/mL collagenase type II (Paesel & Lorei, Hanau, Germany) dissolved in Ham's F12 medium (Gibco, BRL, Eggenstein-Leopoldshafen, Germany) for 100 min. After washing with Ca²⁺- and Mg²⁺-free PBS the ganglia were placed in D-MEM (Dulbecco's modified Eagles medium; Gibco) containing 10 000 U/mL trypsin (Sigma), for 8 min), washed 3 times in D-MEM and centrifuged again. The cell pellets were suspended in Ham's F-12 medium containing 10% heat-inactivated horse serum (Gibco, BRL, Eggenstein-Leopoldshafen, Germany), were collected by centrifugation (500 × g, 8 min), washed 3 times in D-MEM and centrifuged again. The cell pellets were suspended in Ham's F-12 medium containing 10% heat-inactivated horse serum (Gibco), 100 U/mL penicillin (Gibco), 100 µg/mL streptomycin (Gibco), and 10 ng/mL nerve growth factor (NGF, Paesel & Lorei), were centrifuged at 1 000 g for 5 min and plated on poly-L-lysine (200 µg/mL) coated glass cover slips (diameter 13 mm). The cells were incubated at 37 °C in a humidified incubator gassed with 5.0% CO₂ and air. The cells were fed after an overnight setting with standard medium (2 mL) and used in the next 24 hours.

Labelling of cultured DRG neurons with an anti-TRPV4 antibody. The cover slips were transferred into 2% paraformaldehyde in 0.1 M/L phosphate buffer (pH 7.2) for 30 min. After washing with phosphate buffered saline (PBS) cells were incubated for 15 min (120 °C, 1 bar) in 0.1 M citrate buffer (pH 6.0). After cooling down and washing with PBS cells were incubated with 2% normal goat serum (Rockland, Gilbertsville, USA) in PBS TX-100. Thereafter the cells were incubated overnight with an anti-TRPV4 antibody (Alomone Labs, Jerusalem, Israel, # ACC-034) diluted 1:100 in PBS, plus 1% Triton-X100 and 1% gelatine from cold water fish skin at 4 °C in a moist chamber. After 3 times washing with PBS, cover slips were incubated for 2 hours at 20 °C with a Alexa-Fluor 568 goat-anti-rabbit antibody (Thermo Fisher Scientific Waltham, Massachusetts, USA, #A11011), diluted 1:200 in PBS, plus 1% Triton-X100 and 1% gelatine from cold water fish skin. After 3 times washing with PBS cells were dehydrated and embedded in Entellan. To test the specificity of the labelling, the control antibody (the peptide corresponding to amino acid residues 853–871 of rat TRPV4 against which the antibody was raised) was added to the primary antibody in a 10 fold excess, and after preincubation of the control antigen no labelling of DRG neurons was observed. Embedded DRG cells were analysed using a light microscope (Axioplan 2, Zeiss, Jena, Germany) coupled to an image analysing system (Axiovision, Zeiss). From each neuron the mean fluorescence value and the area were determined. All neurons were considered as positive if they showed a fluorescence value above that of neurons from the control incubation (see above). In total about 400 neurons were analysed (from n = 4 independent cultures).

Ca²⁺-imaging. Cultured rat DRG neurons were loaded with 5 µM Fura-2 acetoxyethylmester (Fura-2/AM, Molecular Probes, Leiden, The Netherlands), dissolved in dimethyl sulfoxide (DMSO) and 0.02% pluronic-127 detergent (Molecular Probes) which remained on the cover slips for 30 min at 20 °C. After incubation the neurons were washed several times with N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] (HEPES) buffer
[150 mM NaCl, 5 mM KCl, 10 mM glucose, 10 mM HEPES, 2 mM CaCl₂, 2 mM MgCl₂/(6H₂O)] and then left in the buffer solution for about 20 min to complete cytoplasmatic dye esterification. The glass cover slips with dye-loaded cells were mounted on the stage of a fluorescence microscope (Zeiss) and superfused with HEPES buffer. The cells were illuminated alternately with light of 340 nm (specific for Fura-2 that has bound Ca²⁺) and 380 nm (specific for Ca²⁺-free Fura-2), and light of 510 nm was collected via a cooled CCD camera. The photomultiplier was coupled to a personal computer for data acquisition. Data were collected every 260 ms and stored in sequential files. The images were analysed using software from Zeiss (Axiovision). In each experiment, 340 nm/380 nm ratio values were calculated. To monitor local changes of [Ca²⁺], specific regions of interest were chosen and [Ca²⁺], for these regions was averaged and plotted as a function of time. Each experiment was started by stopping the superfusion. After 20 s 100 µL of the buffer solution plus 0.05% ethanol were added to the bath to exclude mechanical activation of the neurons. After 1 min 100 µL of 4×PDD (10 µM/L in HEPES buffer plus 0.05% ethanol, Sigma) was applied to the bath. To check the vitality of the neurons the cells were finally exposed to 50 mM KCl in HEPES buffer.

Data evaluation and statistics. The action potentials were sorted by shape and amplitude. In the electrophysiological experiments in vivo, we counted the numbers of action potentials that occurred spontaneously in the one-minute-period before stimulation started and those that were evoked by mechanical stimulation. In some figures raw data are presented. In order to allow a comparison between different animals, we calculated the net changes in numbers of action potentials by normalizing to the baseline before application of a test substance. To do so, responses to the same stimuli and ongoing activity of the 1 min recording intervals of each animal were averaged throughout the baseline period. These means were then subtracted from each corresponding response period throughout the application of the test substance in the particular animal. Then the responses to the stimuli of the same type within one block were averaged. In the end, data of animals which underwent the same treatment were averaged. As an additional parameter the mechanical threshold for torque (torque that induced a stable discharge rate of action potentials) was assessed at the beginning of the experiment and at the end of the observation period after application of the compound.

Values are given as mean ± SEM. For statistical analysis of changes within groups we used the Wilcoxon signed rank test or a paired t-test (Student). Significance was accepted at p < 0.05. Significances were calculated with the Instat software package (Graph Pad Instat, San Diego, USA).

Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References
1. Schaible, H.-G. & Grubb, B. D. Afferent and spinal mechanisms of joint pain. Pain 55, 5–54 (1993).
2. Schaible, H.-G. et al. Joint pain. Exp. Brain Res. 196, 153–162 (2009).
3. Etter, A. et al. Pain sensation in human osteoarthritic knee joints is strongly enhanced by diabetes mellitus. Pain 158, 1743–1753 (2017).
4. Liedtke, W. et al. Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell 103, 525–535 (2000).
5. Strotmann, R., Harteneck, C., Nunnenmacher, K., Schultz, G. & Plant, T. D. OTRPC4, a non-selective cation channel that confers sensitivity to extracellular osmolarity. Nat. Cell Biol. 2, 695–702 (2000).
6. Liedtke, W. & Friedman, J. M. Abnormal osmotic regulation in trpv4-mice. Proc. Natl. Acad. Sci. USA 100, 13698–13703 (2003).
7. Levine, D. & Alessandri-Haber, N. TRP channels: Targets for the relief of pain. Biochimica Biophysica Acta 172, 989–1003 (2007).
8. Alessandri-Haber, N., Joseph, E., Dina, O. A., Liedtke, W. & Levine, J. D. TRPV4 mediates pain-related behavior induced by mild hypertonic stimuli in the presence of inflammatory mediator. Pain 118, 70–79 (2005).
9. Alessandri-Haber, N. et al. Hypotonicity induces TRPV4-mediated nociception in rat. Neuron 39, 497–511 (2003).
10. Alessandri-Haber, N., Dina, O. A., Joseph, E. K., Reichling, D. & Levine, J. D. A transient receptor potential vanilloid 4-dependent mechanism of hyperalgesia is engaged by concerted action of inflammatory mediators. J. Neurosci. 26, 3864–3874 (2006).
11. Todaka, H., Haniguchi, J., Satoh, J. I., Mizuno, A. & Suzuki, M. Warm temperature-sensitive TRPV4 plays an essential role in thermal hyperalgesia. J. Biol. Chem. 279, 35133–35138 (2004).
12. Lee, H., Iida, T., Mizuno, A., Suzuki, M. & Caterina, M. J. Altered thermal selection behavior in mice lacking transient receptor potential vanilloid 4. J. Neurosci. 25, 1304–1310 (2005).
13. Suzuki, M., Mizuno, A., Kodaira, K. & Imai, M. Impaired pressure sensation in mice lacking TRPV4. J. Biol. Chem. 278, 22664–22668 (2003).
14. Grant, A. D. et al. Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 channel to cause mechanical hyperalgesia. J. Physiol. 578, 715–733 (2007).
15. Hinata, M. et al. Sensitization of transient receptor potential vanilloid 4 and increasing its endogenous ligand 5,6-epoxyeicosatrienoic acid in rats with monosodiumacetate-induced osteoarthritis. Pain 159, 839–847 (2018).
16. McDougall, J. J., Hanesch, U., Pawlak, M. & Schmidt, R. F. Participation of NK1 receptors in nociceptin-induced modulation of rat knee joint mechanosensitivity. Exp. Brain Res. 137, 249–253 (2001).
17. Gomis, A. et al. Blockade of nociceptive sensory afferent activity of the rat knee joint by the bradykinin B2 receptor antagonist fasitibant. Osteoarthritis Cartilage 21, 1346–1354 (2013).
18. Schaible, H.-G. Nociceptive neurons detect cytokines in arthritis. Arthritis Res. Ther. 16, 470 (2014).
19. Vincent, F. & Duncton, M. A. J. TRPV4 agonists and antagonists. Curr. Top. Med. Chem. 11, 2216–2226 (2011).
20. Jankowski, M. P., Rau, K. K. & Koerber, H. R. Cutaneous TRPM8-expressing sensory afferents are a small population of neurons with unique firing properties. Physiol. Rep. https://doi.org/10.14814/phy2.13234 (2017).
21. Denadai-Souza, A. et al. Role of transient receptor potential vanilloid 4 in rat joint inflammation. Arthritis Rheumatol. 64, 1848–1858 (2012).
22. Segond von Banchet, G. et al. Neuronal IL-17 receptor upregulates TRPV4 but not TRPV1 receptors in DRG neurons and mediates mechanical but not thermal hyperalgesia. Mol. Cell. Neurosci. 52, 152–160 (2013).
23. Ebbringhaus, M. et al. Interleukin-17A is involved in mechanical hyperalgesia but not in the severity of murine antigen-induced arthritis. Sci. Rep., https://doi.org/10.1038/s41598-017-10509-5 (2017).
24. Richter, F. et al. Interleukin-17 sensitizes joint nociceptors for mechanical stimuli and contributes to arthritic pain through neuronal IL-17 receptors in rodents. *Arthritis Rheumatol.* **64**, 4125–4134 (2012).
25. Lee, K. H., Chung, K., Chung, J. M. & Coggshall, R. E. Correlation of cell body size, axon size, and signal conduction velocity for individually labelled dorsal root ganglion cells in the cat. *J. Comp. Neurol.* **243**, 335–346 (1986).
26. Aizawa, N., Wyndaele, J.-J., Homma, Y. & Igawa, Y. Effects of TRPV4 cation channel activation of the primary bladder afferent activities of the rat. *Neurourology Urodynamics* **31**, 148–155 (2012).
27. Wei, X., Edelmayr, R. M., Yan, J. & Dussor, G. Activation of TRPV4 on dural afferents produces headache-related behavior in a preclinical rat model. *Cephalalgia* **31**, 1595–1600 (2011).
28. Vincent, F. et al. Identification and characterization of novel TRPV4 modulators. *Biochem. Biophys. Res. Commun.* **389**, 490–494 (2009).
29. Baratchi, S. et al. The TRPV4 Agonist GSK1016790A regulates the membrane expression of TRPV4 channels. *Front. Pharmacol.* https://doi.org/10.3389/fphar.2019.00006 (2019).
30. Chen, Y. et al. Temporomandibular joint pain: a critical role for Trpv4 in the trigeminal ganglion. *Pain* **154**, 1295–1304 (2013).
31. McNulty, A. L., Leddy, H. A., Liedtke, W. & Guilak, F. TRPV4 as a therapeutic target for joint diseases. *Naunyn-Schmiedeberg’s Arch. Pharmacol.* **388**, 437–450 (2015).
32. Krupkova, O., Zvick, J. & Wuertz-Kozak, K. The role of transient receptor potential channels in joint diseases. *Eur. Cells Materials* **34**, 180–201 (2017).
33. O’Connor, C. J., Leddy, H. A., Benefield, H. C., Liedtke, B. & Guilak, F. TRPV4-mediated mechanotransduction regulates the metabolic response of chondrocytes to dynamic loading. *Proc. Natl. Acad. Sci. USA* **111**, 1316–1321 (2014).
34. Itoh, Y. et al. An environmental sensor, TRPV4 is a novel regulator of intracellular Ca2+ in human synoviocytes. *Am. J. Physiol. Cell Physiol.* **297**, C1082–1090 (2009).
35. Kochukov, M. Y., McNerney, T. A., Fu, Y. & Westlund, K. N. Thermosensitive TRP ion channels mediate cytosolic calcium response in human synoviocytes. *Am. J. Physiol. Cell Physiol.* **291**, C424–432 (2006).
36. Kochukov, M. Y. et al. Tumor necrosis factor-alpha (TNF-alpha) enhances functional thermal and chemical responses of TRP cation channels in human synoviocytes. *J. Pain*. https://doi.org/10.1186/1744-8069-5-49 (2009).
37. Masuyama, R. et al. TRPV4-mediated calcium influx regulates terminal differentiation of osteoclasts. *Cell Metab.* **8**, 257–265 (2008).
38. Mizoguchi, F. et al. Transient receptor potential vanilloid 4 deficiency suppresses unloading-induced bone loss. *J. Cell Physiol.* **216**, 47–53 (2008).
39. Pan, M. N. et al. Functional characterization of TRPV4 as an osmotically sensitive ion channel in porcine articular chondrocytes. *Arthritis Rheumatol.* **60**, 3038–3037 (2009).
40. Nilius, B. & Voets, T. The puzzle of TRPV4 channelopathies. *EMBO Rep.* **14**, 152–163 (2013).
41. Lamande, S. R. et al. Mutations in TRPV4 cause an inherited arthropathy of hands and feet. *Nat. Genetics* **43**, 1142–1146 (2011).
42. Clark, A. L., Votta, B. J., Kumar, S., Liedtke, W. & Guilak, F. Chondroprotective role of the osmotically sensitive ion channel transient receptor potential vanilloid 4. *Arthritis Rheumatol.* **62**, 2973–2983 (2010).
43. O’Connor, C. J. et al. Cartilage-specific knockout of the mechanosensory ion channel TRPV4 decreases age-related osteoarthritis. *Sci. Rep.* https://doi.org/10.1038/srep29053 (2016).
44. Forster, C. & Handwerker, H. O. Automatic classification and analysis of microneurographic spike data using a PC/AT. *J. Neurosci. Methods* **31**, 109–118 (1990).